Archive · 30 Jun 2025
Alembic Pharmaceuticals Receives USFDA Nod for Cancer Drug
Alembic Pharmaceuticals got the green light from the US government to sell a generic version of a cancer drug.
This drug, Doxorubicin Hydrochloride Liposome injection, comes in two strengths and is used to treat different types of cancer like ovarian cancer and Kaposi's sarcoma.
It's the same as a similar drug already available but made by a different company.
The market for this type of drug is estimated to be worth around $29 million.
Alembic Pharmaceuticals received final USFDA approval.
Approval is for generic Doxorubicin Hydrochloride Liposome injection.
The injection comes in 20 mg/10 mL and 50 mg/25 mL single-dose vials.
It's therapeutically equivalent to Baxter Healthcare Corporation's product.
The drug treats ovarian cancer, Kaposi's sarcoma, and multiple myeloma.
- Who
- Alembic Pharmaceuticals
- What
- USFDA approved Alembic Pharmaceuticals' generic cancer treatment injection.
- When
- The approval was announced on June 30, 2025.
- Where
- United States
- Why
- To allow Alembic to sell a generic version of a cancer treatment.
- Company
- Alembic Pharmaceuticals
- Drug Name
- Doxorubicin Hydrochloride Liposome injection
- Approval Agency
- USFDA
- Indications
- Ovarian Cancer, AIDS-Related Kaposi's sarcoma, multiple myeloma
- Strengths
- 20 mg/10 mL, 50 mg/25 mL
- Market Size
- USD 29 million (estimated)